Test can identify aggressive vs. indolent disease, reduce unneeded biopsies
A new validation study has confirmed the novel IsoPSA™ prostate-specific antigen assay’s superiority over conventional tests to detect high-grade, clinically significant prostate cancers.
If used in a clinical setting, the IsoPSA test could reduce unnecessary prostate biopsies by more than 40% while reliably differentiating among high-grade, low-grade and benign disease, the multi-center study found.
Its false-negative rate was acceptably low, and its enhanced ability to identify high-grade tumors when used in concert with multiparametric magnetic resonance imaging (mpMRI)-guided biopsy could one day establish a new diagnostic regimen for prostate cancer, the study’s authors conclude.
“The validation study verifies the clinical utility of this marker to help correctly identify those men at highest risk of prostate cancer, and to avoid biopsy in those at lower risk,” says Eric Klein, MD, Chair of Cleveland Clinic’s Glickman Urological & Kidney Institute and the study’s lead author.
Why a better test is needed